TY - JOUR ID - 26153 TI - Expression of β-tubulin Ⅲ and Survivin in Advance Stage Breast Cancer Correlates with Chemotheraputic Effects of Docetaxel JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2012 PY - 2012 VL - 13 IS - 1 SP - 361 EP - 365 KW - breast cancer KW - Docetaxel KW - β-tubulinⅢ KW - Survivin KW - Chemotherapy DO - N2 - Aims: To investigate the relationship between the expression of β-tubulinⅢ and survivin in advanced breastcancers and chemotherapeutic effects of docetaxel. Methods: Clinical pathological data of 74 patients withadvanced breast cancer were retrospectively analyzed after docetaxel chemotherapy. Expression of β-tubulinⅢand survivin was assessed by immunohistochemistry and analyzed with reference to therapeutical and adverseeffects of docetaxel. Results: The positive expression rate of β-tubulinⅢ was 38.1% (32/84), while that of survivinwas 76.2% (64/84). The effective rate (complete response + partial response) was 52.4%. That for patients withthe positive expression of β-tubulinⅢ or/and survivin was significantly lower than for those with negativeexpression (P<0.05). There were significant differences in the non-progression of median diseases, 1-year and2-year survival rates of between the patients with positive and negative expression (P<0.05). The main side effectswere myelosuppression, alimentary canal response and alopecie, no differences being observed between groups.Conclusions: The combined detection of β-tubulinⅢ and survivin is a predictive index for chemotherapy effectsof docetaxel in metastatic breast cancer. UR - https://journal.waocp.org/article_26153.html L1 - https://journal.waocp.org/article_26153_c0d7414f8560a1c0459a53db0ef6e822.pdf ER -